EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization
EGFR amplification in gliomas is commonly defined by an EGFR/CEP7 ratio of ≥2. In testing performed at a major reference laboratory, a small subset of patients had ≥5 copies of both EGFR and CEP7 yet were not amplified by the EGFR/CEP7 ratio and were designated high polysomy cases. To determine whet...
Gespeichert in:
| Veröffentlicht in: | Journal of neuropathology and experimental neurology 2024-04, Vol.83 (5), p.338-344 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 344 |
|---|---|
| container_issue | 5 |
| container_start_page | 338 |
| container_title | Journal of neuropathology and experimental neurology |
| container_volume | 83 |
| creator | Wilcock, Diane M Goold, Eric Zuromski, Lauren M Davidson, Christian Mao, Qinwen Sirohi, Deepika |
| description | EGFR amplification in gliomas is commonly defined by an EGFR/CEP7 ratio of ≥2. In testing performed at a major reference laboratory, a small subset of patients had ≥5 copies of both EGFR and CEP7 yet were not amplified by the EGFR/CEP7 ratio and were designated high polysomy cases. To determine whether these tumors are more closely related to traditionally defined EGFR-amplified or nonamplified gliomas, a retrospective search identified 22 out of 1143 (1.9%) gliomas with an average of ≥5 copies/cell of EGFR and CEP7 with an EGFR/CEP7 ratio of |
| doi_str_mv | 10.1093/jnen/nlae028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3038426915</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3038426915</sourcerecordid><originalsourceid>FETCH-LOGICAL-c286t-fd3498c8a902b8d928a9103b4d43dba186ba1c8d1016b37d620446d610dd92673</originalsourceid><addsrcrecordid>eNo9kD1PwzAQhi0EgvKxMSOPDISe7cR1RlSVgoQEQjBHTuxQI8cOtjOE38CPJoXCcnfD8746PQidE7gmULL5u9Nu7qzUQMUempGiyDNeLMQ-mgFQmjHg5RE6jvEdAEoo80N0xASHoqBshr5W69vn-XL1tMAb87bBvbdj9N2ITcRR9zLIpLF0CisTk3FNwm3wHd6msOx6a1rTyGS8w8bhN2t8bWVMvpNYRqx00qEzTitcj7i1gw86Nto1ektHkwa8GetglPn86ThFB620UZ_t9gl6vV29LO-yh8f1_fLmIWuo4ClrFctL0QhZAq2FKul0EWB1rnKmakkEn0YjFAHCa7ZQnEKec8UJqAnmC3aCLn97--A_Bh1T1ZnpL2ul036IFQMmcspLUkzo1S_aBB9j0G3VB9PJMFYEqq3_auu_2vmf8Itd81B3Wv3Df8LZN3Rrg_0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3038426915</pqid></control><display><type>article</type><title>EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Wilcock, Diane M ; Goold, Eric ; Zuromski, Lauren M ; Davidson, Christian ; Mao, Qinwen ; Sirohi, Deepika</creator><creatorcontrib>Wilcock, Diane M ; Goold, Eric ; Zuromski, Lauren M ; Davidson, Christian ; Mao, Qinwen ; Sirohi, Deepika</creatorcontrib><description>EGFR amplification in gliomas is commonly defined by an EGFR/CEP7 ratio of ≥2. In testing performed at a major reference laboratory, a small subset of patients had ≥5 copies of both EGFR and CEP7 yet were not amplified by the EGFR/CEP7 ratio and were designated high polysomy cases. To determine whether these tumors are more closely related to traditionally defined EGFR-amplified or nonamplified gliomas, a retrospective search identified 22 out of 1143 (1.9%) gliomas with an average of ≥5 copies/cell of EGFR and CEP7 with an EGFR/CEP7 ratio of <2 displaying high polysomy. Of these cases, 4 had insufficient clinicopathologic data to include in additional analysis, 15 were glioblastomas, 2 were IDH-mutant astrocytomas, and 1 was a high-grade glial neoplasm, NOS. Next-generation sequencing available on 3 cases demonstrated one with a TERT promoter mutation, TP53 mutations in all cases, and no EGFR mutations or amplifications, which most closely matched the nonamplified cases. The median overall survival times were 42.86, 66.07, and 41.14 weeks for amplified, highly polysomic, and nonamplified, respectively, and were not significantly different (p = 0.3410). High chromosome 7 polysomic gliomas are rare but our data suggest that they may be biologically similar to nonamplified gliomas.</description><identifier>ISSN: 0022-3069</identifier><identifier>ISSN: 1554-6578</identifier><identifier>EISSN: 1554-6578</identifier><identifier>DOI: 10.1093/jnen/nlae028</identifier><identifier>PMID: 38605523</identifier><language>eng</language><publisher>England</publisher><ispartof>Journal of neuropathology and experimental neurology, 2024-04, Vol.83 (5), p.338-344</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of American Association of Neuropathologists, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c286t-fd3498c8a902b8d928a9103b4d43dba186ba1c8d1016b37d620446d610dd92673</cites><orcidid>0009-0005-3544-4116</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38605523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilcock, Diane M</creatorcontrib><creatorcontrib>Goold, Eric</creatorcontrib><creatorcontrib>Zuromski, Lauren M</creatorcontrib><creatorcontrib>Davidson, Christian</creatorcontrib><creatorcontrib>Mao, Qinwen</creatorcontrib><creatorcontrib>Sirohi, Deepika</creatorcontrib><title>EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization</title><title>Journal of neuropathology and experimental neurology</title><addtitle>J Neuropathol Exp Neurol</addtitle><description>EGFR amplification in gliomas is commonly defined by an EGFR/CEP7 ratio of ≥2. In testing performed at a major reference laboratory, a small subset of patients had ≥5 copies of both EGFR and CEP7 yet were not amplified by the EGFR/CEP7 ratio and were designated high polysomy cases. To determine whether these tumors are more closely related to traditionally defined EGFR-amplified or nonamplified gliomas, a retrospective search identified 22 out of 1143 (1.9%) gliomas with an average of ≥5 copies/cell of EGFR and CEP7 with an EGFR/CEP7 ratio of <2 displaying high polysomy. Of these cases, 4 had insufficient clinicopathologic data to include in additional analysis, 15 were glioblastomas, 2 were IDH-mutant astrocytomas, and 1 was a high-grade glial neoplasm, NOS. Next-generation sequencing available on 3 cases demonstrated one with a TERT promoter mutation, TP53 mutations in all cases, and no EGFR mutations or amplifications, which most closely matched the nonamplified cases. The median overall survival times were 42.86, 66.07, and 41.14 weeks for amplified, highly polysomic, and nonamplified, respectively, and were not significantly different (p = 0.3410). High chromosome 7 polysomic gliomas are rare but our data suggest that they may be biologically similar to nonamplified gliomas.</description><issn>0022-3069</issn><issn>1554-6578</issn><issn>1554-6578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kD1PwzAQhi0EgvKxMSOPDISe7cR1RlSVgoQEQjBHTuxQI8cOtjOE38CPJoXCcnfD8746PQidE7gmULL5u9Nu7qzUQMUempGiyDNeLMQ-mgFQmjHg5RE6jvEdAEoo80N0xASHoqBshr5W69vn-XL1tMAb87bBvbdj9N2ITcRR9zLIpLF0CisTk3FNwm3wHd6msOx6a1rTyGS8w8bhN2t8bWVMvpNYRqx00qEzTitcj7i1gw86Nto1ektHkwa8GetglPn86ThFB620UZ_t9gl6vV29LO-yh8f1_fLmIWuo4ClrFctL0QhZAq2FKul0EWB1rnKmakkEn0YjFAHCa7ZQnEKec8UJqAnmC3aCLn97--A_Bh1T1ZnpL2ul036IFQMmcspLUkzo1S_aBB9j0G3VB9PJMFYEqq3_auu_2vmf8Itd81B3Wv3Df8LZN3Rrg_0</recordid><startdate>20240419</startdate><enddate>20240419</enddate><creator>Wilcock, Diane M</creator><creator>Goold, Eric</creator><creator>Zuromski, Lauren M</creator><creator>Davidson, Christian</creator><creator>Mao, Qinwen</creator><creator>Sirohi, Deepika</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0005-3544-4116</orcidid></search><sort><creationdate>20240419</creationdate><title>EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization</title><author>Wilcock, Diane M ; Goold, Eric ; Zuromski, Lauren M ; Davidson, Christian ; Mao, Qinwen ; Sirohi, Deepika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c286t-fd3498c8a902b8d928a9103b4d43dba186ba1c8d1016b37d620446d610dd92673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilcock, Diane M</creatorcontrib><creatorcontrib>Goold, Eric</creatorcontrib><creatorcontrib>Zuromski, Lauren M</creatorcontrib><creatorcontrib>Davidson, Christian</creatorcontrib><creatorcontrib>Mao, Qinwen</creatorcontrib><creatorcontrib>Sirohi, Deepika</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuropathology and experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilcock, Diane M</au><au>Goold, Eric</au><au>Zuromski, Lauren M</au><au>Davidson, Christian</au><au>Mao, Qinwen</au><au>Sirohi, Deepika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization</atitle><jtitle>Journal of neuropathology and experimental neurology</jtitle><addtitle>J Neuropathol Exp Neurol</addtitle><date>2024-04-19</date><risdate>2024</risdate><volume>83</volume><issue>5</issue><spage>338</spage><epage>344</epage><pages>338-344</pages><issn>0022-3069</issn><issn>1554-6578</issn><eissn>1554-6578</eissn><abstract>EGFR amplification in gliomas is commonly defined by an EGFR/CEP7 ratio of ≥2. In testing performed at a major reference laboratory, a small subset of patients had ≥5 copies of both EGFR and CEP7 yet were not amplified by the EGFR/CEP7 ratio and were designated high polysomy cases. To determine whether these tumors are more closely related to traditionally defined EGFR-amplified or nonamplified gliomas, a retrospective search identified 22 out of 1143 (1.9%) gliomas with an average of ≥5 copies/cell of EGFR and CEP7 with an EGFR/CEP7 ratio of <2 displaying high polysomy. Of these cases, 4 had insufficient clinicopathologic data to include in additional analysis, 15 were glioblastomas, 2 were IDH-mutant astrocytomas, and 1 was a high-grade glial neoplasm, NOS. Next-generation sequencing available on 3 cases demonstrated one with a TERT promoter mutation, TP53 mutations in all cases, and no EGFR mutations or amplifications, which most closely matched the nonamplified cases. The median overall survival times were 42.86, 66.07, and 41.14 weeks for amplified, highly polysomic, and nonamplified, respectively, and were not significantly different (p = 0.3410). High chromosome 7 polysomic gliomas are rare but our data suggest that they may be biologically similar to nonamplified gliomas.</abstract><cop>England</cop><pmid>38605523</pmid><doi>10.1093/jnen/nlae028</doi><tpages>7</tpages><orcidid>https://orcid.org/0009-0005-3544-4116</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3069 |
| ispartof | Journal of neuropathology and experimental neurology, 2024-04, Vol.83 (5), p.338-344 |
| issn | 0022-3069 1554-6578 1554-6578 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3038426915 |
| source | Oxford University Press Journals All Titles (1996-Current) |
| title | EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T04%3A38%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EGFR/CEP7%20high%20polysomy%20is%20separate%20and%20distinct%20from%20EGFR%20amplification%20in%20glioblastoma%20as%20determined%20by%20fluorescence%20in%20situ%20hybridization&rft.jtitle=Journal%20of%20neuropathology%20and%20experimental%20neurology&rft.au=Wilcock,%20Diane%20M&rft.date=2024-04-19&rft.volume=83&rft.issue=5&rft.spage=338&rft.epage=344&rft.pages=338-344&rft.issn=0022-3069&rft.eissn=1554-6578&rft_id=info:doi/10.1093/jnen/nlae028&rft_dat=%3Cproquest_cross%3E3038426915%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3038426915&rft_id=info:pmid/38605523&rfr_iscdi=true |